 |
62 Diseases |  |
26 Trials |
|
26 Trials |  |
826 News |  |
| «12345678910» |
- Symlin (pramlintide) / AstraZeneca, Byetta (exenatide) / AstraZeneca
Trial completion, Trial primary completion date: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia (clinicaltrials.gov) - Jun 23, 2015
P4, N=35, Completed, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014
- |||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
Enrollment open, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - Jun 20, 2015
P4, N=3270, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- |||| Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
Monotherapy: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (clinicaltrials.gov) - Jun 11, 2015
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Aug 2017
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=60, Enrolling by invitation, Sponsor: University of Colorado, Denver
Trial primary completion date: Jan 2016 --> Aug 2017 Trial primary completion date: Aug 2013 --> Aug 2015
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) - Jun 11, 2015
P3, N=100, Recruiting, Sponsor: Sydney Children's Hospital, Randwick
Trial primary completion date: Aug 2013 --> Aug 2015 Trial primary completion date: Dec 2012 --> Dec 2016
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change, Trial primary completion date: Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120) (clinicaltrials.gov) - Jun 2, 2015
P2, N=36, Active, not recruiting, Sponsor: Wake Forest School of Medicine
Trial primary completion date: Dec 2012 --> Dec 2016 N=90 --> 36 | Trial primary completion date: Mar 2013 --> Sep 2015
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Enrollment change: A Trial Comparing the Glycaemic Control of Levemir (clinicaltrials.gov) - Jun 1, 2015
P4, N=46, Completed, Sponsor: Novo Nordisk A/S
N=90 --> 36 | Trial primary completion date: Mar 2013 --> Sep 2015 Active, not recruiting --> Completed | N=140 --> 46
- ||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
New P4 trial, HEOR, Real-world evidence, Real-world: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (clinicaltrials.gov) - May 21, 2015
P4, N=3270, Not yet recruiting, Sponsor: Sanofi
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change, Trial termination: Use of Levemir (clinicaltrials.gov) - May 19, 2015
P2/3, N=5, Terminated, Sponsor: Nationwide Children's Hospital
Active, not recruiting --> Completed | N=140 --> 46 N=20 --> 5 | Recruiting --> Terminated; PI left the institution
- ||||| Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
Monotherapy: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (clinicaltrials.gov) - May 4, 2015
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=20 --> 5 | Recruiting --> Terminated; PI left the institution Recruiting --> Active, not recruiting
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: A Trial Comparing the Glycaemic Control of Levemir (clinicaltrials.gov) - Apr 20, 2015
P4, N=140, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Jun 2015
- Victoza (liraglutide) / Novo Nordisk
Trial completion: Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics (clinicaltrials.gov) - Apr 20, 2015
P4, N=36, Completed, Sponsor: Mountain Diabetes and Endocrine Center
Trial primary completion date: Jan 2015 --> Jun 2015 Active, not recruiting --> Completed
- Trial completion, Enrollment change: REACT4SENSOR: Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=8, Completed, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Enrolling by invitation --> Completed | N=10 --> 8
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Trial primary completion date: Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=105, Completed, Sponsor: St. Luke's-Roosevelt Hospital Center
Enrolling by invitation --> Completed | N=10 --> 8 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015
- Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical: Basal21: Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes (clinicaltrials.gov) - Feb 10, 2015
P=N/A, N=26, Recruiting, Sponsor: University of Padova
- Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=10, Completed, Sponsor: Northumbria University
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment closed: A Trial Comparing the Glycaemic Control of Levemir (clinicaltrials.gov) - Jan 9, 2015
P4, N=140, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment open, Trial initiation date: The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (clinicaltrials.gov) - Nov 18, 2014
P4, N=100, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Nov 2014
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 14, 2014
P3, N=362, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Nov 2014 Active, not recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=94, Recruiting, Sponsor: St. Luke's-Roosevelt Hospital Center
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Dec 2014
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=18, Completed, Sponsor: University of Calgary
Trial primary completion date: Jul 2014 --> Dec 2014 N=130 --> 18
- Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 21, 2014
P3, N=350, Completed, Sponsor: Novo Nordisk A/S
N=130 --> 18 Trial primary completion date: Jul 2013 --> Feb 2013
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes (clinicaltrials.gov) - Aug 19, 2014
P4, N=200, Recruiting, Sponsor: Mackay Memorial Hospital
Trial primary completion date: Jul 2013 --> Feb 2013 Trial primary completion date: Jun 2013 --> Oct 2014
- | New P4 trial: Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (clinicaltrials.gov) - Aug 19, 2014
P4, N=200, Recruiting, Sponsor: Mackay Memorial Hospital
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: KILOS: Observational Study on Levemir (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=580, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jun 2013 --> Oct 2014 N=365 --> 580
- Enrollment change: Safety of NovoMix (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=3421, Completed, Sponsor: Novo Nordisk A/S
N=365 --> 580 N=1462 --> 3421
- Enrollment change: An Observational Study to Compare the Safety and Effectiveness of NovoMix (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=3131, Completed, Sponsor: Novo Nordisk A/S
N=1462 --> 3421 N=2589 --> 3131
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: An Observational Study on Efficacy and Safety in Subjects Using Levemir (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=798, Completed, Sponsor: Novo Nordisk A/S
N=2589 --> 3131 N=1000 --> 798
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Observational Study of Safety and Tolerability of Levemir (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=2286, Completed, Sponsor: Novo Nordisk A/S
N=1000 --> 798 N=3299 --> 2286
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial initiation date: A Trial Comparing the Glycaemic Control of Levemir (clinicaltrials.gov) - Aug 12, 2014
P4, N=140, Recruiting, Sponsor: Novo Nordisk A/S
N=3299 --> 2286 Initiation date: Jan 2013 --> Jun 2013
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Enrollment closed: A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 8, 2014
P3, N=346, Active, not recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Jan 2013 --> Jun 2013 Recruiting --> Active, not recruiting
- Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=2134, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2004 --> Oct 2006
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial initiation date: A Trial Comparing the Glycaemic Control of Levemir (clinicaltrials.gov) - Jun 18, 2014
P4, N=140, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Oct 2004 --> Oct 2006 Initiation date: Jun 2013 --> Jan 2013
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P1 trial: A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin (clinicaltrials.gov) - Jun 13, 2014
P1, N=13, Completed, Sponsor: Novo Nordisk A/S
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment open, Combination therapy: A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (clinicaltrials.gov) - Jun 13, 2014
P3, N=358, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Jun 2013 --> Jan 2013 Not yet recruiting --> Recruiting
- Lantus (insulin glargine) / Sanofi
Clinical: REACT4SENSOR: Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=10, Enrolling by invitation, Sponsor: Medical University of Graz
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial primary completion date: Levemir-Body Composition and Energy Metabolism (clinicaltrials.gov) - May 5, 2014
P4, N=42, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Apr 2014
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Levemir-Body Composition and Energy Metabolism (clinicaltrials.gov) - May 5, 2014
P4, N=42, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Trial primary completion date: Jul 2014 --> Apr 2014 N=80 --> 42
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Levemir-Body Composition and Energy Metabolism (clinicaltrials.gov) - May 5, 2014
P4, N=42, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
N=80 --> 42 Recruiting --> Completed
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P3 trial, Combination therapy: A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (clinicaltrials.gov) - May 4, 2014
P3, N=358, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (clinicaltrials.gov) - Mar 9, 2014
P3, N=1095, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion: Action to Control Cardiovascular Risk in Diabetes (ACCORD) (clinicaltrials.gov) - Feb 6, 2014
P3, N=10251, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- metformin / Generic mfg.
Enrollment change: CIMT: The Copenhagen Insulin and Metformin Therapy Trial (clinicaltrials.gov) - Feb 1, 2014
P4, N=415, Completed, Sponsor: Steno Diabetes Center
Active, not recruiting --> Completed N=900 --> 415
- metformin / Generic mfg.
Trial completion: CIMT: The Copenhagen Insulin and Metformin Therapy Trial (clinicaltrials.gov) - Feb 1, 2014
P4, N=415, Completed, Sponsor: Steno Diabetes Center
N=900 --> 415 Active, not recruiting --> Completed
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
New P4 trial: TRICIDIA: Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes (clinicaltrials.gov) - Jan 27, 2014
P4, N=60, Recruiting, Sponsor: Centre Hospitalier Universitaire Dijon
- |||||| Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
Monotherapy: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (clinicaltrials.gov) - Jan 26, 2014
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
Monotherapy: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (clinicaltrials.gov) - Jan 9, 2014
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes (clinicaltrials.gov) - Dec 9, 2013
P4, N=52, Completed, Sponsor: University Hospital, Toulouse
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Victoza (liraglutide) / Novo Nordisk
Enrollment closed: Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics (clinicaltrials.gov) - Nov 7, 2013
P4, N=36, Active, not recruiting, Sponsor: Mountain Diabetes and Endocrine Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P4 trial: The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (clinicaltrials.gov) - Oct 20, 2013
P4, N=100, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center